Peptide-based cancer vaccines are designed to target specific tumor epitopes—such as KRAS, telomerase, or survivin—yet their efficacy is often limited by MHC restriction and the typically monoclonal nature of the T cell response [60]. This evidence concerns the gene BIRC5 and neoplasm.